Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease.  Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases.  Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics. 

Biotechnology

Volastra

Volastra's headquarters in Boston, MA, United States

This department manages clinical research and operational strategies to advance medical innovations.

Clinical Development

The Advisory Team at Volastra Therapeutics, Inc. comprises a group of esteemed experts who provide strategic guidance and insights to support the company's mission of developing novel therapies to treat and prevent metastatic disease. Leveraging their extensive backgrounds in cancer research, clinical practice, and therapeutic development, the advisors assist in refining research directions, evaluating clinical strategies, and fostering collaborations to accelerate the advancement of innovative treatments based on chromosomal instability (CIN) mechanisms.

Advisory Team

This department oversees strategic direction and high-level management for the organization.

Executive Leadership

The Scientific Research Team at Volastra focuses on elucidating the mechanisms and pathways by which chromosomal instability (CIN) drives the formation and proliferation of metastatic disease. Comprised of a diverse group of scientists specializing in areas such as tumor immunology, computer vision, and image analytics, the team collaborates to discover novel therapeutic targets and develop innovative treatments to prevent and treat metastasis.

Scientific Research Team

This department focuses on developing and managing business strategies and portfolio initiatives.

Business Strategy

This department is responsible for advancing research and development in various fields of chemistry, including biochemistry and structural biology.

People (3)

Jobs (0)

Other teams

Advisory Team

Executive Leadership

Scientific Research Team

Business Strategy

Chemistry Division